Physician profile
Brian E Bass
NPI 1144222787
$1,806.56
in general payments reported to CMS, 2019-2025
25 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $34.90 · 2022: $116 · 2023: $664 · 2024: $514 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $335.12 | 2019-2025 | |
| Astellas Pharma US INC | $194.29 | 2022-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $173.66 | 2023-2025 | Phexxi, Solosec, Phexx |
| Shield Therapeutics INC | $159.78 | 2022-2024 | Accrufer |
| Exeltis, USA INC. | $147.30 | 2022-2025 | Slynd |
| Coopersurgical, INC. | $99.62 | 2023-2024 | Endosee, Paragard T 380a |
| Organon LLC | $90.72 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $90.48 | 2023-2025 | Myfembree |
| Abbvie INC. | $69.11 | 2023-2024 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $66.28 | 2022-2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Therapeuticsmd, INC. | $61.66 | 2019 | |
| Mayne Pharma Commercial LLC | $52.45 | 2023 | |
| Pfizer INC. | $50.92 | 2019-2024 | |
| Biogen, INC. | $29.31 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $26.97 | 2023-2024 | Ova1 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.77 | 2024 | |
| Exact Sciences Corporation | $23.30 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $21.86 | 2023 | Stratafix, Enseal, Harmonic |
| Daiichi Sankyo INC. | $16.65 | 2019 | |
| Minerva Surgical, INC | $16.22 | 2024 | |
| Mylan Pharmaceuticals INC. | $16.03 | 2019 | |
| Merck Sharp & Dohme LLC | $15.68 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.13 | 2019 | |
| Allergan, INC. | $11.25 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.